Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
2019 · Journal for ImmunoTherapy of Cancer · 256 citations
https://doi.org/10.1186/s40425-019-0706-x
J
Julie Collins
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
36
Papers
826
Citations
12
h-index
15
i10-index
Julie Collins is an academic researcher from AstraZeneca (United States). The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Immunotherapy and Immune Responses & CAR-T cell therapy research. The author has an h-index of 12, co-authored 31 publications.
ORCID: 0000-0001-5702-4693Papers by this author
worksCancer vaccines: Enhanced immunogenic modulation through therapeutic combinations
2017 · Human Vaccines & Immunotherapeutics · 113 citations
https://doi.org/10.1080/21645515.2017.1364322
Emergent Renal Dysfunction with Colistin Pharmacotherapy
2013 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 30 citations
https://doi.org/10.1002/phar.1271
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
2024 · Nature Communications · 22 citations
https://doi.org/10.1038/s41467-024-46961-x
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort
2025 · Nature Communications · 9 citations
https://doi.org/10.1038/s41467-025-59210-6
A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor
2023 · Contemporary Clinical Trials Communications · 8 citations
https://doi.org/10.1016/j.conctc.2023.101110
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat